Substrate
science

Firefly Aerospace Reports $81 Million Q1 Revenue and $1.3 Billion Backlog

Firefly Aerospace announced record revenue of $81 million for the first quarter of 2026, alongside a $1.3 billion backlog. The company highlighted wins in the Artemis program and defense sectors. It also provided an outlook for the full year during its earnings call.

seekingalpha.com
1 source·May 5, 1:24 AM(1 day ago)·1m read
Firefly Aerospace Reports $81 Million Q1 Revenue and $1.3 Billion BacklogU.S. Space Force photo by Staff Sgt. Joshua LeRoi / Wikimedia (Public domain)
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

Com reported. 3 billion as of the end of Q1 2026, reflecting strong demand for its services. In the same period, Firefly Aerospace secured wins related to NASA's Artemis program, which aims to return humans to the moon.

Additionally, the company achieved defense-related wins during Q1 2026, expanding its portfolio in government contracts. During its Q1 2026 earnings call, Firefly Aerospace provided an outlook for the full year 2026, outlining expectations for growth and operations.

Key Facts

Revenue milestone
Firefly Aerospace reported $81 million in revenue for Q1 2026
Backlog figure
Firefly Aerospace reported a $1.3 billion backlog for Q1 2026
Program wins
Firefly Aerospace secured wins related to the Artemis program in Q1 2026
Defense achievements
Firefly Aerospace secured defense wins in Q1 2026
Future outlook
Firefly Aerospace provided an outlook for 2026 during its Q1 2026 earnings call

Story Timeline

5 events
  1. 2026-05-05

    Firefly Aerospace provides 2026 outlook during Q1 earnings call

    1 sourceseekingalpha.com
  2. Q1 2026

    Firefly Aerospace secures Artemis program wins

    1 sourceseekingalpha.com
  3. Q1 2026

    Firefly Aerospace secures defense wins

    1 sourceseekingalpha.com
  4. Q1 2026

    Firefly Aerospace reports $1.3 billion backlog

    1 sourceseekingalpha.com
  5. Q1 2026

    Firefly Aerospace reports $81 million revenue

    1 sourceseekingalpha.com

Potential Impact

  1. 01

    Enhanced positioning in space and defense sectors from Artemis and defense wins

  2. 02

    Improved revenue projections for 2026 based on provided outlook

  3. 03

    Potential stock price increase for FLY due to strong Q1 performance

  4. 04

    Increased investor confidence from record revenue and backlog

Transparency Panel

Sources cross-referenced1
Confidence score70%
Synthesized bySubstrate AI
Word count75 words
PublishedMay 5, 2026, 1:24 AM
Bias signals removed1 across 1 outlet
Signal Breakdown
positive framing 1

Related Stories

Hantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Riskdeccanchronicle.com
science8 hrs agoDeveloping

Hantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Risk

A hantavirus outbreak on the MV Hondius cruise ship has killed three passengers and sickened seven others, prompting an international response coordinated by the World Health Organization. The ship, carrying 147 people from 23 nationalities, is set to sail to Spain's Canary Islan…

Stat
Cbs News
2 sources
Imperial College London Study Analyzes Changes in Wildfire Weather Patterns in Northern Irelandtechjuice.pk
science2 hrs agoDeveloping

Imperial College London Study Analyzes Changes in Wildfire Weather Patterns in Northern Ireland

A new report from Imperial College London highlights growing wildfire threats in Northern Ireland due to more favorable conditions, especially in spring. Researchers note increased drought and fire-prone weather, exacerbated by climate change. The findings point to longer fire se…

The Bbc
1 source
FDA Commissioner Defends Drug Rejection DecisionsThe U.S. Food and Drug Administration / Wikimedia (Public domain)
science14 hrs agoFraming55Framing risk55/100Lede misdirection foregrounds commissioner's defense over substantive drug rejections; inherited negative valence from sources on agency turmoil and backlash.Click to jump to full framing analysis

FDA Commissioner Defends Drug Rejection Decisions

The FDA commissioner defended recent drug rejections in a CNBC interview, citing adherence to scientific reviews amid reports of agency turmoil. Criticism includes a high-profile denial of a melanoma treatment from Replimune and pressure from President Trump over vape approvals.…

cnbc.com
Wall Street Journal
joemygod.com
3 sources